Eucure Approved for US Phase II Trials of Combination Therapies
publication date: Jul 7, 2021
Eucure Biopharma, a Beijing immunotherapy subsidiary of Biocytogen, has been approved to start US Phase II trials of two antibodies. The candidates are YH001, targeting CTLA-4, and YH003, targeting CD40. Both molecules will be tested in combination with Junshi Biosciences' anti-PD-1, toripalimab. Eucure, which develops innovative immunotherapies to meet clinical needs for global markets, has built a product pipeline of more than 10 targets. The parent, Biocytogen, is a CRO that provides gene-modified animal models for drug discovery and preclinical testing. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.